Work

Abstract LB-211: A novel dual epigenetic/kinase inhibitory platform: SF2523 and analogues as first-in-class PI3K/BRD4 inhibitors

Year: 2016

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2016-lb-211

Authors: Alok Singh, Shweta Joshi, Joseph R. Garlich, Guillermo Morales, Tatiana Kutateladze, Forest Andrews, Donald Durden

Institutions: University of California San Diego, SignalRx Pharmaceuticals (United States), University of Colorado Denver

Language: English

Topic: Protein Degradation and Inhibitors

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2494926864

Cites:

Cited by: 1

Related to: 10